ArticleToxicological research2025
Cd stabilizes HIF-1α under normoxic conditions via lysine-63-linked ubiquitination and induces ER stress and cell proliferation.
Article in Toxicological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Oyster hydrolysate attenuates osteoarthritis progression by modulating inflammatory signaling and extracellular matrix homeostasis.Nutrition research and practice · 2026Article
- From environmental exposure to retinal pathology: epidemiological and mechanistic insights into multi-metal driven ocular diseases.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Article
- Protective Effects ofJournal of microbiology and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cadmium, a carcinogenic and toxic substance released into the environment, has emerged as a potent activator of lysine-63 ubiquitination, and lysine-63 is a crucial regulator of signal transduction pathways. Although critical, very little information is currently available about how the activation of lysine 63 ubiquitination by Cd might contribute to cancers and inflammatory diseases. The present study provides the first evidence that Cd stabilizes hypoxia-inducible factor-1-alpha, a transcription factor, under normoxic conditions via lysine 63 ubiquitination. Cd induces the accumulation of lysine 63 polyubiquitinated proteins. Importantly, Cd-induced ubiquitination does not prevent oxidative damage or proteasome impairment. Instead, we demonstrated that Cd activates lysine 63 ubiquitination and amplifies its accumulation by overloading the capacity of the autophagy pathway, thus promoting endoplasmic reticulum stress and cell death. At the molecular level, Cd-induced lysine 63 polyubiquitination is correlated with the stabilization of hypoxia-inducible factor-1-alpha, which translocates into the nucleus and promotes the expression of oncogenes such as interleukin 8 and vascular endothelial growth factor. Strikingly, prolonged cell exposure to high Cd concentrations induces increased lysine-63 polyubiquitination, which promotes aggresome formation, thus preventing this protein from interacting with its downstream nuclear targets. Our results showed that Cd is an activator of K63-linked ubiquitination that stabilizes and promotes the accumulation of HIF-1α, which blocks autophagy, thus resulting in endoplasmic reticulum stress. In addition, a small amount of HIF-1α was observed in the nucleus. We therefore propose that the aberrant activation of lysine 63 polyubiquitination by the carcinogen Cd could promote cell proliferation and inflammation at low levels, while high levels lead to cell death. Supplementary Information: The online version contains supplementary material available at 10.1007/s43188-024-00266-9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.